MedPath

Impact on the Nutritional State and the Quality of Life

Completed
Conditions
Cancer
Interventions
Other: answering questionnare in differents time of the treatment
Registration Number
NCT01687335
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Brief Summary

The prevalence of malnutrition in cancerous patients varies between 50% and 80%. It is variable in function: the location and the extension of the tumor, of the general state , of age, of the socio-economic class and the pain. The health consequences of a malnutrition are very important: aggravation of the state of health, complications of treatment, hospitalization, alteration of the quality of life and decrease the survival, and the treatment response.

Nutrition being very important in patients, there are recommendations for the nutritional care of these patients, formulated by the European Society for Clinical Nutrition and Metabolism. The investigators do not know to what extent these recommendations are respected in practice and their influence on the nutritional status and the quality of life of patients.

The investigators therefore propose to assess the conformity of the nutritional care patients in clinical practice in relation to the European recommendations and in a second time to assess the influence of this compliance or non-compliance on the nutritional status clinical and biological of cancerous patients under chemotherapy, on their quality of life, on their response to treatment and on their survival.

The investigators will try to identify factors that may be linked to the non-compliance such as the characteristics of the cancer disease, socio-demographic characteristics of the subject and the factors related to the structure in which it is supported.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
102
Inclusion Criteria
  • 18-year-old subject in 85 years in the inclusion
  • Subject presenting a cancerous pathology requiring a systematic treatment by exclusive chemotherapy for a minimal duration of three months with a plan of 3 cures of chemotherapy with an interval between the cures of 21 days
  • Presenting subject one of these 4 cancerous pathologies: cancer of the aéro-digestive ways superiors, sarcomas, colorectal cancers, broncho-lung cancers
  • Subject having the capacity of lira and to understand(include) French
  • Subject having signed lit(enlightened) consent
  • Subject taken care for its cancerous pathology in one of the partner services of the project
  • Subject affiliated to the national insurance scheme
Exclusion Criteria
  • Subject having benefited from a major surgical operation in 4 weeks preceding the inclusion
  • Subject having benefited from a radiotherapy in two weeks before the inclusion
  • Subject minor(miner), pregnant woman, subject incapable to give its consent, subject under supervision(guardianship) - guardianship

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
cancerous patientsanswering questionnare in differents time of the treatmentthe patients benefiting from treatment by chemotherapy.
Primary Outcome Measures
NameTimeMethod
improvement of their survival3 YEARS
quality of life's improvement3 YEARS
improvement of treatment effectiveness,3 YEARS
Secondary Outcome Measures
NameTimeMethod
the answer to the treatment3 years
improvement of the screening of the undernutrition3 YEARS
the estimation of the survival with regard to the nutritional state of the patient.3 years

Trial Locations

Locations (1)

Assistance Publique Hopitaux de Marseille

🇫🇷

Marseille, France

© Copyright 2025. All Rights Reserved by MedPath